In: J Pickup, G Williams (eds) Textbook of diabetes, 3rd edn
Incretin-based therapies for treatment of obesity The concept of incretin-based treatment of overweight and obesity was driven by the effect of native GLP-1 and GLP-1R agonists on appetite and satiety in combination with an observed loss in body weight in trials investigating liraglutide for the treatment of type 2 diabetes [27]
Overview of its approval and use in medical treatments The FDA approved semaglutide in 2017 to assist with Type 2 diabetes, including those on basal insulin
Blonde L, Belousova L, Fainberg U, Garcia-Hernandez PA, Jain SM, Kaltoft MS, et al
To view a copy of this licence, visit About this article Cite this article Lin, LC., Chen, JY., Huang, T.TM
Appeals are built using structured medical logic, insurance requirements, andin paid planshuman review and support from an appeal specialist